GLP-1 Agonists and Eye Health: Understanding Risks and Monitoring Strategies

Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) are increasingly prescribed for managing type 2 diabetes and obesity, offering significant metabolic benefits. However, emerging clinical observations have raised concerns about potential ocular complications associated with their use. This review addresses the critical need to synthesize current clinical evidence, explore potential underlying mechanisms, and provide risk-stratified monitoring recommendations for patients undergoing GLP-1 RA therapy.

The review concluded that while GLP-1 RAs are highly effective in improving systemic metabolic parameters, a subset of patients, particularly those with pre-existing diabetic retinopathy, may experience a transient worsening of their retinopathy early in treatment. This phenomenon is often attributed to rapid metabolic shifts, which can acutely impact retinal blood flow and oxygenation. Proposed mechanisms include alterations in VEGF (vascular endothelial growth factor, a protein promoting blood vessel growth) levels and increased retinal inflammation, though further research is needed to fully elucidate these pathways. The review also noted that the long-term systemic benefits of GLP-1 RAs generally outweigh these potential transient ocular risks for the majority of patients. The most significant finding is the emphasized need for a risk-stratified monitoring approach to identify and manage patients at higher risk for ocular complications during GLP-1 RA therapy.